Cullinan Therapeutics, Inc.
CGEM
$12.69
-$0.44-3.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.40% | 2.08% | 7.26% | 9.67% | 36.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.38% | 13.80% | 51.51% | 27.93% | 21.02% |
| Operating Income | -0.38% | -13.80% | -51.51% | -27.93% | -21.02% |
| Income Before Tax | -6.70% | -24.78% | -66.69% | -29.89% | -19.77% |
| Income Tax Expenses | -- | -- | -- | -- | 100.83% |
| Earnings from Continuing Operations | -6.43% | -24.78% | -66.69% | -29.89% | -86.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | -6.43% | -24.78% | -66.69% | -30.56% | -100.17% |
| EBIT | -0.38% | -13.80% | -51.51% | -27.93% | -21.02% |
| EBITDA | -0.38% | -13.81% | -51.59% | -27.98% | -21.06% |
| EPS Basic | -5.31% | -23.21% | -55.50% | 4.67% | -46.24% |
| Normalized Basic EPS | -5.58% | -23.22% | -55.50% | 4.37% | 5.83% |
| EPS Diluted | -5.31% | -23.21% | -55.50% | 4.67% | -46.24% |
| Normalized Diluted EPS | -5.58% | -23.22% | -55.50% | 4.37% | 5.83% |
| Average Basic Shares Outstanding | -- | 1.27% | 7.20% | 36.95% | 36.89% |
| Average Diluted Shares Outstanding | 0.84% | 1.27% | 7.20% | 36.95% | 36.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |